Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:24835rdf:typepubmed:Citationlld:pubmed
pubmed-article:24835lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:24835lifeskim:mentionsumls-concept:C0600260lld:lifeskim
pubmed-article:24835lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:24835lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:24835pubmed:issue4lld:pubmed
pubmed-article:24835pubmed:dateCreated1978-5-24lld:pubmed
pubmed-article:24835pubmed:abstractTextMany patients with pulmonary disease may have significant airflow obstruction. Bronchodilatation is an important aspect of treatment and can be achieved with beta-adrenergic agonists, methylxanthine derivatives, and anticholinergic agents. These can be used singly or in combination, depending on the severity of obstruction.lld:pubmed
pubmed-article:24835pubmed:languageenglld:pubmed
pubmed-article:24835pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:citationSubsetAIMlld:pubmed
pubmed-article:24835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:24835pubmed:statusMEDLINElld:pubmed
pubmed-article:24835pubmed:monthAprlld:pubmed
pubmed-article:24835pubmed:issn0032-5481lld:pubmed
pubmed-article:24835pubmed:authorpubmed-author:PlummerA LALlld:pubmed
pubmed-article:24835pubmed:issnTypePrintlld:pubmed
pubmed-article:24835pubmed:volume63lld:pubmed
pubmed-article:24835pubmed:ownerNLMlld:pubmed
pubmed-article:24835pubmed:authorsCompleteYlld:pubmed
pubmed-article:24835pubmed:pagination36-41, 44-6, 48lld:pubmed
pubmed-article:24835pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Hu...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Th...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-In...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Re...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Ae...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Pa...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Br...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-In...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Ad...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Lu...lld:pubmed
pubmed-article:24835pubmed:meshHeadingpubmed-meshheading:24835-Ad...lld:pubmed
pubmed-article:24835pubmed:year1978lld:pubmed
pubmed-article:24835pubmed:articleTitleChoosing a drug regimen for obstructive pulmonary disease. 1. Agents to achieve bronchodilatation.lld:pubmed
pubmed-article:24835pubmed:publicationTypeJournal Articlelld:pubmed